Trial reportBMC cancer2026
Efficacy and safety of 7-day aerosolized epigallocatechin-3-gallate in oncologic patients with COVID-19 pneumonia.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06924749 (Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary：Phase II Clinical Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary：Phase II Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOncologic patients are vulnerable to prolonged or severe COVID-19 due to immunosuppression and comorbidities. Our initial Phase I/II clinical trial has showed that epigallocatechin-3-gallate (EGCG), a catechin monomer isolated from tea, exhibits favorable safety profiles with therapeutic effects against COVID-19 pneumonia. This phase II, open-label, randomized controlled trial further evaluated the efficacy and safety of 7-day aerosolized epigallocatechin-3-gallate (EGCG) in oncologic patients with COVID-19 pneumonia.
methodsThis trial was conducted from June 2023 to May 2024. Patients were randomized (2:1) to receive aerosolized EGCG plus standard treatment or standard treatment alone. The primary endpoint was CT imaging improvement. Secondary endpoints included symptom resolution and the safety of EGCG.
results114 patients were randomized, with 108 eligible (71 in EGCG group, 37 in control group). The EGCG group showed significantly greater CT improvement (P = 0.004) and faster symptom resolution for fever (P = 0.035), cough (P = 0.048), and dyspnea (P = 0.015). Improvement rates were higher in the EGCG group for fever (95% confidence interval: 1.380 -10.352) and dyspnea (95% confidence interval:1.750-60.446). Post-treatment lactate dehydrogenase levels were significantly lower in the EGCG group (P = 0.028). Safety profiles were comparable, with only mild adverse events observed in the EGCG group.
conclusionsAerosolized EGCG significantly improved both radiological and clinical outcomes with a favorable safety profile in oncologic patients with COVID-19 pneumonia, although broader application requires further validation in larger multi-center trials. TRIAL REGISTRY: ClinicalTrials.gov, TRN: NCT06924749, Registration date: 22 August 2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.